Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 201–300 of 1,006
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
Tavares, V., Marques, I. S., de Melo, I. G., Assis, J., Pereira, D., & Medeiros, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031845 · Cited by 171
“Namely, tumour mutational burden (TMB), meaning the number of somatic mutations per unit of a tumour-interrogated genome, has surfaced as an important marker of response to immune checkpoint inhibition [202].”
BackgroundXu, Q., Wang, J., Sun, Y., Lin, Y., Liu, J., Zhuo, Y., Huang, Z., Huang, S., Chen, Y., Chen, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02091 · Cited by 160
“Target lesion size, mm, median (range) 49 (15-217)”
CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
Lin, A., Qi, C., Wei, T., Li, M., Cheng, Q., Liu, Z., Luo, P., & Zhang, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac129 · Cited by 152
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Daniel, P. M., Sabri, S., Chaddad, A., Meehan, B., Jean‐Claude, B. J., Rak, J. W., & Abdulkarim, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00041 · Cited by 155
“High mutational burden has been identified as the best predictor of response to this treatment option, regardless of disease (41).”
BackgroundCutaneous adverse events caused by immune checkpoint inhibitors
Quach, H. T., Johnson, D. B., LeBoeuf, N. R., Zwerner, J. P., & Dewan, A. K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.054 · Cited by 160
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
Damato, B. E., Dukes, J. D., Goodall, H., & Carvajal, R. D. (2019) · Cancers · doi:10.3390/cancers11070971 · Cited by 161
“Additionally, PD-L1 expression has been shown to positively correlate with responses to anti-PD-(L)1 inhibitors [73,76].”
BackgroundResultInfluentialFigueiredo, C. R., Kalirai, H., Sacco, J. J., Azevedo, R., Duckworth, A. D., Slupsky, J. R., Coulson, J. M., & Coupland, S. E. (2020) · The Journal of Pathology · doi:10.1002/path.5384 · Cited by 168
“While UMs have been partly ascribed to a low mutational burden [4,5], evidence of specific TCR gene expression in tumour-infiltrating lymphocytes (TILs) [6], promising responses to adoptive cell therapy using TILs [7], and encouraging results on Journal of Pathology J Pathol 2020; 250: 420–439 Published online in Wile…”
ResultRational combinations of immunotherapy with radiotherapy in ovarian cancer
Herrera, F. G., Irving, M. B., Kandalaft, L. E., & Coukos, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30401-2 · Cited by 162
Li, J., Chen, Y., Li, Y., Liu, N., & Ma, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01317-7 · Cited by 162
“Consistent with these notions, highly-mutated malignancies with an abundance of neoantigens, such as melanoma, NSCLC, and HNSC C, are more sensitive to ICB treatment [14, 15].”
BackgroundSingle‐cell analyses reveal suppressive tumor microenvironment of human colorectal cancer
Mei, Y., Xiao, W., Hu, H., Lu, G., Chen, L., Sun, Z., Lü, M., Ma, W., Jiang, T., Gao, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.422 · Cited by 171
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., De Geest, B., Breckpot, K., Dirix, L., Feldman, S. A., van Criekinge, W., Thielemans, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 142
Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2803 · Cited by 146
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Russell, L., Peng, K. W., Russell, S. J., & Díaz, R. M. (2019) · BioDrugs · doi:10.1007/s40259-019-00367-0 · Cited by 158
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 153
Dendritic Cells in Cancer Immunology and Immunotherapy
Hato, L., Atienza, Á. V., Eguren‐Santamaría, I., Perez‐Gracia, J. L., Rodríguez, J., Pérez‐Larraya, J. G., Sarobe, P., Inogés, S., de Cerio, A. L. D., & Santisteban, M. (2024) · Cancers · doi:10.3390/cancers16050981 · Cited by 167
“By analyzing the presence of these mutations, the relevance of the tumor mutational burden (TMB) and CPI efficacy has been demonstrated [164–166] at the same time that many neoantigens (neoAgs) have been identified, allowing the detection of tumor-specific T-cells and fine characterization of their…”
BackgroundOu, Z., Lin, S., Qiu, J., Ding, W., Ren, P., Chen, D., Wang, J., Tong, Y., Wu, D., Chen, A., et al. (2022) · Advanced Science · doi:10.1002/advs.202203040 · Cited by 173
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
Wu, A. A., Bever, K. M., Ho, W. J., Fertig, E. J., Niu, N., Zheng, L., Parkinson, R. M., Durham, J. N., Onners, B., Ferguson, A. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1025 · Cited by 156
Self-citationEmerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
Sen, T., Takahashi, N., Chakraborty, S., Takebe, N., Nassar, A. H., Karim, N. A., Puri, S., & Naqash, A. R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00914-x · Cited by 166
“Although a high TMB is known to be associated with an immunologically active tumour microenvironment (TME) owing to efficient neoantigen processing and presentation, ICIs have demonstrated limited efficacy in patients with SCLC 21 .”
Gameiro, S. F., Ghasemi, F., Barrett, J. W., Koropatnick, J. D., Nichols, A. C., Mymryk, J. S., & Vareki, S. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1498439 · Cited by 154
“Indeed, a significant correlation exists between immune checkpoint inhibitor response and mutational load across cancer sites.(38) A variety of studies have compared various immunological parameters between HPV+ and HPV- HNSCC and generally concluded that HPV+ HNSCC are immune “hot” tumors, with markedly more immune i…”
BackgroundBallhausen, A., Przybilla, M. J., Jendrusch, M., Haupt, S., Pfaffendorf, E., Seidler, F., Witt, J., Hernandez Sanchez, A., Urban, K., Draxlbauer, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18514-5 · Cited by 139
Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 144
Lawlor, R. T., Mattiolo, P., Mafficini, A., Hong, S., Piredda, M. L., Taormina, S. V., Malleo, G., Marchegiani, G., Pea, A., Salvia, R., et al. (2021) · Cancers · doi:10.3390/cancers13133119 · Cited by 149
“Of all available immunotherapies, a high-TMB is strictly associated with response to anti-PD-1 therapies, as clarified by a pooled analysis of 27 tumor types [9,10].”
BackgroundPeptide-based PET quantifies target engagement of PD-L1 therapeutics
Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa‐Shah, P., Wharram, B. L., Lesniak, W. G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122216 · Cited by 144
Self-citationLong, H., Jia, Q., Wang, L., Fang, W., Wang, Z., Jiang, T., Zhou, F., Zheng, J., Huang, J., Zhou, L., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.018 · Cited by 153
Qi, X., Li, F., Wu, Y. M., Chen, C., Han, P., Wang, J., & Yang, X. (2019) · Nature Communications · doi:10.1038/s41467-019-10088-1 · Cited by 143
Akagi, K., Oki, E., Taniguchi, H., Nakatani, K., Aoki, D., Kuwata, T., & Yoshino, T. (2021) · Cancer Science · doi:10.1111/cas.14798 · Cited by 137
Muñoz, N. M., Williams, M. L., Dixon, K. A., Dupuis, C. J., McWatters, A., Avritscher, R., Manrique, S. Z., McHugh, K. J., Murthy, R., Tam, A. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001800 · Cited by 140
Recent advances in therapeutic cancer vaccines
Zaidi, N., Jaffee, E. M., & Yarchoan, M. M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00820-z · Cited by 163
“This is especially the case in tumours with higher tumour mutational burden (TMB), for example most melanomas, which often have hundreds of high-quality neoantigens 105 .”
InfluentialSelf-citationCurrent and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Guo, W., Wu, Z., Chen, J., Guo, S., You, W., Wang, S., Ma, J., Wang, H., Wang, X.-X., Wang, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004381 · Cited by 144
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
Considerations for designing preclinical cancer immune nanomedicine studies
Jiang, W., Wang, Y., Wargo, J. A., Lang, F. F., & Kim, B. Y. S. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00817-9 · Cited by 142
Lecocq, Q., Keyaerts, M., Devoogdt, N., & Breckpot, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010075 · Cited by 133
“Among these next-generation ICPs, lymphocyte activating gene-3 (LAG-3, CD233) has emerged as an eminent target in the development of cancer treatment and holds substantial prognostic value.”
BackgroundInfluentialPD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 153
The landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 148
Applying artificial intelligence for cancer immunotherapy
Xu, Z., Wang, X., Zeng, S., Ren, X., Yan, Y., & Gong, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.007 · Cited by 126
“Moreover, ML models using gene mutation features might serve as biomarkers for immunotherapy prognosis and guidance 75,82,83 .”
MethodAdoptive CD8+ T cell therapy against cancer:Challenges and opportunities
Jiang, X., Jiang, X., Liu, M., Xing, H., Wang, Z., Huang, L., Mellor, A. L., Wang, W., & Wu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.017 · Cited by 141
Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
Wu, H., Wang, Z., Zhao, Q., Chen, D., He, M.-M., Yang, L.-P., Wang, Y., Jin, Y., Ren, C., Luo, H., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.116 · Cited by 142
“TMB determined by the FDAauthorized MSK-IMPACT panel or the FDA-approved FoundationOne CDx panel, was proven to be the predictor of response to ICIs in multiple cancer types (7,19,37).”
BackgroundInfluentialKrebs, M. G., Malapelle, U., André, F., Paz-Ares, L., Schuler, M., Thomas, D. M., Vainer, G., Yoshino, T., & Rolfo, C. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4457 · Cited by 126
Bomze, D., Hasan Ali, O., Bate, A., & Flatz, L. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3221 · Cited by 129
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Smad3 is essential for polarization of tumor-associated neutrophils in non-small cell lung carcinoma
Chung, J. Y., Tang, P. C., Chan, M. K., Xue, V. W., Huang, X.-R., Ng, C. S. H., Zhang, D., Leung, K.-T., Wong, C.-K., Lee, T.-L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37515-8 · Cited by 133
Next batter up! Targeting cancers with KRAS-G12D mutations
Zeissig, M. N., Ashwood, L. M., Kondrashova, O., & Sutherland, K. D. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.010 · Cited by 128
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
Krasniqi, E., Barchiesi, G., Pizzuti, L., Mazzotta, M., Venuti, A., Maugeri‐Saccà, M., Sanguineti, G., Massimiani, G., Sergi, D., Carpano, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0798-2 · Cited by 143
Rejection of immunogenic tumor clones is limited by clonal fraction
Gejman, R. S., Chang, A. Y., Jones, H. F., DiKun, K., Hakimi, A. A., Schietinger, A., & Scheinberg, D. A. (2018) · eLife · doi:10.7554/elife.41090 · Cited by 126
“Tumors with high mutation burdens—which are more likely to have immunogenic neoantigens (Van Allen et al., 2015; Yarchoan et al., 2017; Snyder et al., 2014)—and tumors that have mismatch repair (MMR) deficiency or microsatellite”
BackgroundSuccessful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
Galanina, N., Goodman, A. M., Cohen, P. R., Frampton, G. M., & Kurzrock, R. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0121 · Cited by 129
“Viral antigens are foreign and, thus, potentially strong immune stimulants that can lead to a robust response to checkpoint blockade (28).”
BackgroundNEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
Zhang, X., Huang, X., Xu, J., Li, E., Lao, M., Tang, T., Zhang, G., Guo, C., Zhang, X., Chen, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24769-3 · Cited by 139
Stratigos, A., Dessinioti, C., Garbe, C., Lebbé, C., Amaral, T., Bataille, V. A., Dréno, B., Dummer, R., Fargnoli, M. C., Forsea, A., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113252 · Cited by 155
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens
Pan, R., Chung, W., Chu, M.-T., Chen, S.-J., Chen, H.-C., Zheng, L., & Chung, W. (2018) · Journal of Immunology Research · doi:10.1155/2018/4325874 · Cited by 133
Li, Z., Song, W., Rubinstein, M., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 119
“anti-PD-1/PD-L1 agents whose exome sequencing information were available [37].”
BackgroundColon Cancer in Young Adults: Trends and Their Implications
Weinberg, B. A., & Marshall, J. L. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0756-8 · Cited by 132
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
“…clinical implementation. ctDNA-informed patient selection for cancer immunotherapy: blood TMB TMB has been linked with therapeutic responses to ICI 52–56 ; as a high number of somatic mutations would encode for neoepitopes presented on the surface of tumor cells, triggering an antitumor immune…”
BackgroundInsights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
“Tumor Neoantigens As previously mentioned, studies have repeatedly shown that tumors with a high mutational load possess a high number of neoantigens and are more responsive to ICB (173).”
BackgroundPeters, S., Dziadziuszko, R., Morabito, A., Felip, E., Gadgeel, S. M., Cheema, P. K., Cobo, M., Andric, Z. G., Barrios, C. H., Yamaguchi, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01933-w · Cited by 129
Belmontes, B., Sawant, D. V., Zhong, W., Tan, H. L. E., Kaul, A. M., Aeffner, F., O’Brien, S. A., Chun, M. G. H., Noubade, R., Eng, J. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1524 · Cited by 126
PD-L1 testing by immunohistochemistry in immuno-oncology
Vranić, S., & Gatalica, Z. (2023) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.7953 · Cited by 142
“In two recent comprehensive pan-cancer studies exploring up to 27 different cancer types, high TMB correlated well with the response to immune checkpoint inhibitors (26, 27).”
BackgroundKong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 136
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 134
Microsatellite instability in prostate cancer by PCR or next-generation sequencing
Hempelmann, J. A., Lockwood, C. M., Konnick, E. Q., Schweizer, M. T., Antonarakis, E. S., Lotan, T. L., Montgomery, B., Nelson, P. S., Klemfuss, N. M., Salipante, S. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0341-y · Cited by 123
Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review
Tagliaferri, L., Lancellotta, V., Fionda, B., Mangoni, M., Casà, C., Stefani, A. D., Pagliara, M. M., D’Aviero, A., Schinzari, G., Chiesa, S., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1903827 · Cited by 123
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
Ambrosini, M., Rousseau, B., Manca, P., Artz, O., Marabelle, A., André, T., Maddalena, G., Mazzoli, G., Intini, R., Cohen, R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.009 · Cited by 133
Cancer vaccines: current status and future directions
Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 135
“While higher mutation burden leads to stronger specific T cell responses and better clinical outcomes with ICIs, it also enables cancer to develop immune escape and drug resistance [16–18].”
Fujisawa, Y., Yoshikawa, S., Minagawa, A., Takenouchi, T., Yokota, K., Uchi, H., Noma, N., Nakamura, Y., Asai, J., Kato, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2110 · Cited by 122
Corti, F., Lonardi, S., Intini, R., Salati, M., Fenocchio, E., Belli, C., Borelli, B., Brambilla, M., Prete, A. A., Quarà, V., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.043 · Cited by 126
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 131
Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma
Chan, J. Y., Lim, J. Q., Yeong, J. P.-S., Ravi, V., Guan, P., Boot, A., Tay, T. K. Y., Selvarajan, S., Nasir, N. D. M., Loh, J. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139080 · Cited by 119
Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers
Saini, S. K., Ørskov, A. D., Bjerregaard, A.-M., Unnikrishnan, A., Holmberg-Thydén, S., Borch, A., Jensen, K. V., Anande, G., Bentzen, A. K., Marquard, A. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19464-8 · Cited by 101
Oka, M., Xu, L., Suzuki, T., Yoshikawa, T., Sakamoto, H., Uemura, H., Yoshizawa, A. C., Suzuki, Y., Nakatsura, T., Ishihama, Y., et al. (2021) · Genome Biology · doi:10.1186/s13059-020-02240-8 · Cited by 108
YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
Hu, J. M., Qiu, D., Yu, A., Hu, J., Deng, H., Li, H., Yi, Z., Chen, J., & Zu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.607224 · Cited by 132
Wang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 123
“DESERT TUMOURS AND RESISTANCE TO ICT TMB has emerged as a potential underlying cause of ‘cold’ tumours and resistance to the ICT [11].”
BackgroundInfluentialGraham, L. S., Montgomery, B., Cheng, H. H., Yu, E. Y., Nelson, P. S., Pritchard, C., Erickson, S., Alva, A., & Schweizer, M. T. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233260 · Cited by 114
“Hypermutation, in turn, is associated with higher expression of tumor neoantigens which facilitates immune recognition [5].”
BackgroundPD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 122
“Well-known biomarkers of response to checkpoint inhibitors such as PD-L1 expression [28,29] and high mutational burden [40] could be present in some subgroups of PCa patients.”
BackgroundProgress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 127
“74 between TMB and anti–PD-1/PD-L1 immunotherapy response suggests that 55% of the differences in objective response rate (ORR) across cancer types may be explained by TMB (12).”
BackgroundInfluentialSomatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure
Akdemir, K. C., Le, V. T., Kim, J. M., Killcoyne, S., King, D. A., Lin, Y., Tian, Y., Inoue, A., Amin, S. B., Robinson, F. S., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0708-0 · Cited by 124
Matikas, A., Zerdes, I., Lövrot, J., Richard, F., Sotiriou, C. P., Bergh, J. C. S., Valachis, A., & Foukakis, T. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1131 · Cited by 129
“The routine implementation of PD-1/PD-L1 inhibition in the treatment of breast cancer has lagged behind, presumably due to its perceived lower immunogenicity (7, 8).”
BackgroundSi, H., Kuziora, M., Quinn, K. J., Helman, E., Ye, J., Liu, F., Scheuring, U., Peters, S., Rizvi, N. A., Brohawn, P. Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3771 · Cited by 114
“Among many factors that may contribute to the response, tumor mutational burden (TMB) derived from the total somatic mutation count, a surrogate for tumor neoantigen load, has been shown to correlate with the efficacy of immune checkpoint inhibitors in clinical trials (11, 12).”
BackgroundScientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti, L., Peikert, T., Robinson, B. W. S., Scherpereel, A., Tsao, A. S., de Perrot, M., Woodard, G. A., Jablons, D. M., Wiens, J., Hirsch, F. R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.011 · Cited by 112
“It has been known for some time that MPM is a cancer that can be sensitive to immunotherapy, and some immunotherapies are currently being tested.91 Nonetheless, at the moment there are no randomized clinical trials examining immunotherapy versus standard therapy that could provide strong support for the use of immunot…”
BackgroundInfluentialOsipov, A., Lim, S. J., Popović, A., Azad, N. S., Laheru, D. A., Zheng, L., Jaffee, E. M., Wang, H., & Yarchoan, M. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0458 · Cited by 125
Self-citationSeliger, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122168 · Cited by 129
“PD-L1 amplification and deletion were associated with TMB evaluated by next generation sequencing based comprehensive profiling [69,70].”
MethodImmunotherapy in Colorectal Cancer: Current and Future Strategies
Ooki, A., Shinozaki, E., & Yamaguchi, K. (2021) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2020-064 · Cited by 118
“dMMR/MSI-H mCRC patients have a better response to ICIs than would be predicted by the status of TMB, whereas in patients with pMMR/MSS, the response is worse than would be predicted[93].”
BackgroundZhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
“Conversely, sarcoma, prostate cancer, and ovarian cancer display lower TMB as well as primary resistance to PD-1inhibition (26, 27).”
BackgroundKašíková, L., Raková, J., Hensler, M., Láníčková, T., Tománková, J., Pasulka, J., Drozenová, J., Mojžíšová, K., Fialová, A., Vosahlikova, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46873-w · Cited by 129
“…(especially in the form of microsatellite instability) and the consequent accrual of non-synonymous DNA mutations (which increase the likelihood of malignant cells to present novel antigenic determinants) have also been associated with superior ICI sensitivity across several tumor types 30,31 .”
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110
“In addition, a linear correlation between tumor mutational burden (TMB) and ORRs with anti-PD-1/PD-L1 agents in multiple solid tumors, including NSCLC, has been reported [103], but EGFR-mutated NSCLCs have a lower TMB (median mutational load: 60) compared with other NSCLCs (TP53 mutated: 325; KRAS mutated: 179; STK11…”
BackgroundPD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
van Gulijk, M., van Krimpen, A., Schetters, S., Eterman, M., van Elsas, M., Mankor, J., Klaase, L., de Bruijn, M., van Nimwegen, M., van Tienhoven, T., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abn6173 · Cited by 110
“SCLC, NSCLC, and mesothelioma patient cohorts Patients with advanced malignant pleural mesothelioma, stage IV SCLC, and stage IV NSCLC in this study were enrolled in the MULTOMAB study (Netherlands Trial Registry: NTR7015; local ethics board study number MEC16–011).”
BackgroundInfluentialRizzo, A., Cusmai, A., Giovannelli, F., Acquafredda, S., Rinaldi, L., Misino, A., Montagna, E. S., Ungaro, V., Lorusso, M., & Palmiotti, G. (2022) · Cancers · doi:10.3390/cancers14061404 · Cited by 116
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy
Mathew, M., Zade, M., Mezghani, N., Patel, R. D., Wang, Y., & Momen‐Heravi, F. (2020) · Cancers · doi:10.3390/cancers12102825 · Cited by 118
“Moreover, EVs can monitor T-cell reactivity in patients who are treated by immune checkpoint blockade therapy [27].”
BackgroundBroos, K., Lecocq, Q., Raes, G., Devoogdt, N., Keyaerts, M., & Breckpot, K. (2018) · Theranostics · doi:10.7150/thno.24762 · Cited by 114
“, the role of PD-L1 expression on host cells [23,24].”
BackgroundBiomimetic Nanoparticle Vaccines for Cancer Therapy
Kroll, A. V., Jiang, Y., Zhou, J., Holay, M., Fang, R. H., & Zhang, L. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800219 · Cited by 110
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 114
“Neoantigens are able to trigger the activation of cytotoxic T-cells [127] and make cancer cells more immunogenic.”
BackgroundAntibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
Chen, Z., Kankala, R. K., Yang, Z., Li, W., Xie, S., Li, H., Chen, A., & Zou, L. (2022) · Theranostics · doi:10.7150/thno.72594 · Cited by 119
“In general, the objective response rate of programmed death 1 (PD-1) immune checkpoint inhibitors (ICIs) to unstable microsatellite cancers is about 35% [11].”
BackgroundEndris, V., Buchhalter, I., Allgäuer, M., Rempel, E., Lier, A., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., Neumann, O., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32002 · Cited by 105
Cimen Bozkus, C., Roudko, V., Finnigan, J. P., Mascarenhas, J., Hoffman, R., Iancu-Rubin, C., & Bhardwaj, N. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1356 · Cited by 105
“Recent work by Cristescu and colleagues corroborate such observations by demonstrating that factors, such as a T cell–inflamed microenvironment, can independently predict response to PD-1 blockade even when the TMB is low (43).”
BackgroundInfluentialWinograd, P., Hou, S., Court, C. M., Lee, Y., Chen, P., Zhu, Y., Sadeghi, S., Finn, R. S., Teng, P., Wang, J. J., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1577 · Cited by 114
“(10-12,18) In other malignancies, expression of PD-L1 or PD-1 by the primary tumor,(36) tumor mutational burden,(37,38) T-cell infiltration of the tumor,(39) and microsatellite instability-high or presence of DNA mismatch repair gene defects(40) have all been associated with response to immunotherapy; unfortunately, e…”
BackgroundBiomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer
Sholl, L. M. (2021) · Modern Pathology · doi:10.1038/s41379-021-00932-5 · Cited by 112
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
“) such as malignant melanomas and squamous cell carcinomas of the lungs [81,82].”
BackgroundHsu, K.-H., Huang, Y.-H., Tseng, J., Chen, K., Ku, W., Su, K., Chen, J. J. W., Chen, H., Yu, S., Yang, T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.021 · Cited by 109
Towards Immunotherapy for Pediatric Brain Tumors
Wang, S. S., Bandopadhayay, P., & Jenkins, M. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.009 · Cited by 106
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.